Sanofi's Sarclisa gains new US multiple myeloma indication

The FDA has approved Sanofi’s Sarclisa (isatuximab) in combination with a new chemotherapy regimen for advanced multiple myeloma, building on a first approval last year.

Blackstone funds new trials of Sanofi's Sarclisa in myeloma

Sanofi has agreed a deal with life sciences investor Blackstone to help fund clinical trials of a new formulation of Sarclisa for blood cancer multiple myeloma, accelerating its development

Kiadis Pharma and Sanofi to unlock power of natural killer c...

Sanofi has struck an exclusive rights deal with Dutch biotech Kiadis focused on combining modified natural killer cells with the French pharma’s blood cancer antibody Sarcl

Sanofi builds case for Sarclisa, challenging J&J’s Darzalex

Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma mark

Sanofi gets first OK for isatuximab for myeloma, challenging...